Last €10.31 EUR
Change Today -0.014 / -0.14%
Volume 200.0
3O8 On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 1:51 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

omeros corp (3O8) Snapshot

Open
€10.21
Previous Close
€10.32
Day High
€10.51
Day Low
€10.21
52 Week High
07/3/14 - €13.98
52 Week Low
08/16/13 - €3.47
Market Cap
349.5M
Average Volume 10 Days
20.0
EPS TTM
--
Shares Outstanding
33.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OMEROS CORP (3O8)

omeros corp (3O8) Related Bloomberg News

View More Bloomberg News

omeros corp (3O8) Related Businessweek News

No Related Businessweek News Found

omeros corp (3O8) Details

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes products targeting inflammation, coagulopathies, and disorders of the central nervous system. Its clinical products include Omidria, which has completed two Phase III clinical trials for use during intraocular lens replacement, including cataract and other lens replacement surgery; OMS103 that is in Phase III clinical program for use during arthroscopic procedures, such as partial meniscectomy surgery; and OMS824, which is in Phase II clinical trial for the treatment of CNS disorders comprising schizophrenia and Huntington's disease. Its clinical programs also consist of OMS721 that is in Phase II clinical trial for the treatment of various complement-related diseases and disorders, including thrombotic microangiopathies; OMS405, which is in Phase II clinical trial for the treatment and prevention of addiction to substances of abuse; and OMS201 that has completed Phase 1/Phase 2 clinical trial for use during urological procedures, such as ureterscopy for removal of ureteral or renal stones. The company’s preclinical products and development programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders, such as Parkinson's disease; and OMS616 for the control of blood loss during surgery, or resulting from trauma or other hyperfibrinolytic conditions. Its preclinical products also include G protein-coupled receptors platform for multiple disorders across therapeutic area; GPR17 for demyelinating disorders; and antibody platform for the discovery of monoclonal antibodies. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.

75 Employees
Last Reported Date: 03/13/14
Founded in 1994

omeros corp (3O8) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $664.6K
Principal Financial Officer, Chief Accounting...
Total Annual Compensation: $79.7K
Vice President of Patent, General Counsel and...
Total Annual Compensation: $342.5K
Compensation as of Fiscal Year 2013.

omeros corp (3O8) Key Developments

Omeros Corporation Presents at Washington Biotechnology & Biomedical Association 14th Annual Life Science Innovation Northwest 2014, Jun-19-2014 03:00 PM

Omeros Corporation Presents at Washington Biotechnology & Biomedical Association 14th Annual Life Science Innovation Northwest 2014, Jun-19-2014 03:00 PM. Venue: Washington State Convention Center, Seattle, Washington, United States.

Omeros Corporation - Special Call

To discuss the receipt FDA approval of Omidria for use in cataract and other intraocular lens replacement procedures

Omeros Corporation Receives FDA Approval of Omidria for Use in Cataract and Other Intraocular Lens Replacement Procedures

Omeros Corporation announced that the U.S. Food and Drug Administration has approved Omidria (phenylephrine and ketorolac injection) 1%/0.3% for use during cataract surgery or intraocular lens replacement (ILR) to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative pain. The approval comes with no post-marketing commitments other than the previously agreed study of Omidria for use in pediatric patients, which, if successfully completed, makes the drug eligible for an additional six months of marketing exclusivity in the U.S. Omidria, the commercial product from Omeros’ PharmacoSurgery platform, is a proprietary combination of a mydriatic (pupil-dilating) agent and an anti-inflammatory agent that is added to irrigation solution standardly used during cataract surgery and other ILR procedures (e.g., refractive lens exchange), collectively the most common surgical procedures performed in the U.S. at nearly four million annually. Omidria is the only FDA-approved product for intraocular use that prevents intraoperative miosis and reduces postoperative pain, providing consistent and predictable management of both of these ILR-related problems for ophthalmic surgeons and their patients. In pivotal trials in which all patients received standard pupil-dilating and anesthetic agents prior to surgery, Omidria demonstrated statistically significant and clinically meaningful improvement in the prevention of miosis and reduction of postoperative pain relative to placebo. Ocular adverse reactions in the trials were similar between the Omidria and placebo groups and included eye irritation, posterior capsule opacification, increased intraocular pressure and anterior chamber inflammation. With FDA approval of Omidria, Omeros is completing preparations for a late summer/early fall 2014 U.S. product launch.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
3O8:GR €10.31 EUR -0.014

3O8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 3O8.
View Industry Companies
 

Industry Analysis

3O8

Industry Average

Valuation 3O8 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 717.5x
Price/Book 91.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 648.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OMEROS CORP, please visit www.omeros.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.